Breast cancer treatment: How a new AI tool could help patients avoid unnecessary chemotherapy

The U.S. Food and Drug Administration (FDA) has cleared ArteraAI Breast, an AI-powered tool aimed at helping oncologists determine whether certain breast cancer patients require aggressive chemotherapy or could safely forgo it. The platform is the first FDA-approved AI-based risk stratification tool for early-stage hormone receptor-positive (HR+), HER2-negative invasive breast cancer, analyzing digital pathology slides and clinical data to predict the likelihood of cancer spreading or recurring. Developed to address challenges in personalized treatment, ArteraAI Breast categorizes patients into low-risk or high-risk groups for distant metastasis. The AI model was trained using data from over 8,500 breast cancer patients enrolled in clinical trials, generating an AI-based risk score to guide treatment decisions. This could help oncologists avoid exposing patients to unnecessary toxicity while ensuring high-risk cases receive appropriate care. Breast cancer remains the most commonly diagnosed cancer among women worldwide, with 2.3 million cases and 670,000 deaths reported globally in 2022 by the World Health Organization. Current methods like the Oncotype DX genomic test, which predicts recurrence risk, can be expensive, time-consuming, and inaccessible in low-resource settings. ArteraAI Breast offers a faster alternative by leveraging pathology slides already generated during routine diagnosis, potentially reducing delays and costs if validated in real-world settings. The tool targets a clinical 'grey zone' where decisions about chemotherapy for early-stage HR+ breast cancer patients—particularly post-menopausal women with node-negative disease—are uncertain. Experts suggest AI could improve detection rates while maintaining low false positives, though it is intended as a support tool alongside doctors rather than a replacement. Adoption of AI in breast cancer treatment varies globally. While many centers in Europe, the UK, and the U.S. are already integrating AI tools, adoption in India remains in early stages. The technology could streamline treatment decisions, reduce unnecessary recalls, and improve long-term efficiency in healthcare systems.